title: Effects of the nitric oxide/cGMP system compared with the cAMP system on airway mucus secretion in the rat.
abstract: Mucus secretion of the airways is under the control of a variety of intracellular second messenger systems. Cyclic nucleotides such as cGMP, coupled to the recently discovered nitric oxide system, and cAMP are of outstanding interest in this respect. The present study used the modified Ussing chamber technique and mucins labelled with (35)SO(4) to investigate mucus secretion in the rat trachea to clarify the contribution of these different second messenger systems to the control of mucin secretion.A variety of drugs affecting either the generation or the breakdown of the respective cyclic nucleotides were used. Neither drugs interfering with nitric oxide synthase nor the phosphodiesterase isoenzyme responsible for cGMP breakdown nor cGMP analogues were able to affect mucus secretion. In contrast, stimulation of adenylate cyclase or inhibition of the respective phosphodiesterase resulted in a potent increase of mucus secretion. In conclusion, we failed to show the involvement of the nitric oxide/cGMP system, whereas the cAMP system seems to be a very efficient regulator of mucus secretion in the rat trachea.
authors.affiliation: Department of Internal Medicine, Medizinische Poliklinik, Philipps-University of Marburg, Baldingerstrasse, D-35043 Marburg, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Bredenbröker
authors.forename: D
authors.initials: D
authors.lastname: Dyarmand
authors.forename: U
authors.initials: U
authors.lastname: Meingast
authors.forename: H C
authors.initials: HC
authors.lastname: Fehmann
authors.forename: P
authors.initials: P
authors.lastname: Staats
authors.forename: P
authors.initials: P
authors.lastname: Von Wichert
authors.forename: U
authors.initials: U
authors.lastname: Wagner
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000067956:Adenylyl Cyclase Inhibitors; D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D001120:Arginine / Q000494:pharmacology; D009320:Atrial Natriuretic Factor / Q000494:pharmacology; D000242:Cyclic AMP / Q000502:physiology*; D006152:Cyclic GMP / Q000502:physiology*; D020536:Enzyme Activators / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000378:metabolism; D008297:Male; D009077:Mucins / Q000378:metabolism; D009093:Mucus / Q000378:metabolism*; D009569:Nitric Oxide / Q000378:metabolism / Q000502:physiology*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013462:Sulfur Radioisotopes; D014132:Trachea / Q000378:metabolism / Q000502:physiology*
chemical_list: D000067956:Adenylyl Cyclase Inhibitors; D020536:Enzyme Activators; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D009077:Mucins; D020030:Nitric Oxide Donors; D010726:Phosphodiesterase Inhibitors; D013462:Sulfur Radioisotopes; D009569:Nitric Oxide; D009320:Atrial Natriuretic Factor; D001120:Arginine; D000242:Cyclic AMP; D019001:Nitric Oxide Synthase; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D000262:Adenylyl Cyclases; D006152:Cyclic GMP